338 related articles for article (PubMed ID: 19736928)
21. Synthesis and biological evaluation of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
Kim DK; Jung SH; Lee HS; Dewang PM
Eur J Med Chem; 2009 Feb; 44(2):568-76. PubMed ID: 18467006
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Jin CH; Krishnaiah M; Sreenu D; Rao KS; Subrahmanyam VB; Park CY; Son JY; Sheen YY; Kim DK
Bioorg Med Chem; 2011 Apr; 19(8):2633-40. PubMed ID: 21435890
[TBL] [Abstract][Full Text] [Related]
23. R-268712, an orally active transforming growth factor-β type I receptor inhibitor, prevents glomerular sclerosis in a Thy1 nephritis model.
Terashima H; Kato M; Ebisawa M; Kobayashi H; Suzuki K; Nezu Y; Sada T
Eur J Pharmacol; 2014 Jul; 734():60-6. PubMed ID: 24726873
[TBL] [Abstract][Full Text] [Related]
24. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor beta 1 type 1 receptor.
Kim DK; Kim J; Park HJ
Bioorg Med Chem Lett; 2004 May; 14(10):2401-5. PubMed ID: 15109621
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles as inhibitors of transforming growth factor-β type I receptor (ALK5).
Guo C; Zhang C; Li X; Li W; Xu Z; Bao L; Ding Y; Wang L; Li S
Bioorg Med Chem Lett; 2013 Nov; 23(21):5850-4. PubMed ID: 24055046
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Mohan AV; Park CY; Son JY; Sheen YY; Kim DK
Bioorg Med Chem Lett; 2011 Oct; 21(20):6049-53. PubMed ID: 21911290
[TBL] [Abstract][Full Text] [Related]
28. Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5).
Singh J; Ling LE; Sawyer JS; Lee WC; Zhang F; Yingling JM
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):437-45. PubMed ID: 15338953
[TBL] [Abstract][Full Text] [Related]
29. 5-(1,3-Benzothiazol-6-yl)-4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazole derivatives as potent and selective transforming growth factor-β type I receptor inhibitors.
Amada H; Sekiguchi Y; Ono N; Koami T; Takayama T; Yabuuchi T; Katakai H; Ikeda A; Aoki M; Naruse T; Wada R; Nozoe A; Sato M
Bioorg Med Chem; 2012 Dec; 20(24):7128-38. PubMed ID: 23117174
[TBL] [Abstract][Full Text] [Related]
30. 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Park HJ; Park SJ; Sheen YY; Kim DK
Bioorg Med Chem; 2014 May; 22(9):2724-32. PubMed ID: 24704197
[TBL] [Abstract][Full Text] [Related]
31. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.
Ermoli A; Bargiotti A; Brasca MG; Ciavolella A; Colombo N; Fachin G; Isacchi A; Menichincheri M; Molinari A; Montagnoli A; Pillan A; Rainoldi S; Sirtori FR; Sola F; Thieffine S; Tibolla M; Valsasina B; Volpi D; Santocanale C; Vanotti E
J Med Chem; 2009 Jul; 52(14):4380-90. PubMed ID: 19555113
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of 2-benzylamino-4(5)-(6-methylpyridin-2-yl)-5(4)-([1,2,4]triazolo[1,5-a]-pyridin-6-yl)thiazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Krishnaiah M; Jin CH; Sreenu D; Subrahmanyam VB; Rao KS; Son DH; Park HJ; Kim SW; Sheen YY; Kim DK
Eur J Med Chem; 2012 Nov; 57():74-84. PubMed ID: 23047226
[TBL] [Abstract][Full Text] [Related]
33. Assessment of the putative binding conformation of a pyrazolopyridine class of inhibitors of MAPKAPK2 using computational studies.
Miglani R; Cliffe IA; Voleti SR
Eur J Med Chem; 2010 Jan; 45(1):98-105. PubMed ID: 19850376
[TBL] [Abstract][Full Text] [Related]
34. Selection of fragments for kinase inhibitor design: decoration is key.
Czodrowski P; Hölzemann G; Barnickel G; Greiner H; Musil D
J Med Chem; 2015 Jan; 58(1):457-65. PubMed ID: 25437144
[TBL] [Abstract][Full Text] [Related]
35. Discovery of novel imidazo[1,2-a]pyridines as inhibitors of the insulin-like growth factor-1 receptor tyrosine kinase.
Ducray R; Simpson I; Jung FH; Nissink JW; Kenny PW; Fitzek M; Walker GE; Ward LT; Hudson K
Bioorg Med Chem Lett; 2011 Aug; 21(16):4698-701. PubMed ID: 21775140
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Jin CH; Sreenu D; Krishnaiah M; Subrahmanyam VB; Rao KS; Nagendra Mohan AV; Park CY; Son JY; Son DH; Park HJ; Sheen YY; Kim DK
Eur J Med Chem; 2011 Sep; 46(9):3917-25. PubMed ID: 21696866
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
Sawyer JS; Beight DW; Britt KS; Anderson BD; Campbell RM; Goodson T; Herron DK; Li HY; McMillen WT; Mort N; Parsons S; Smith EC; Wagner JR; Yan L; Zhang F; Yingling JM
Bioorg Med Chem Lett; 2004 Jul; 14(13):3581-4. PubMed ID: 15177479
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of 1-(6-methylpyridin-2-yl)-5-(quinoxalin-6-yl)-1,2,3-triazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Li F; Park Y; Hah JM; Ryu JS
Bioorg Med Chem Lett; 2013 Feb; 23(4):1083-6. PubMed ID: 23294702
[TBL] [Abstract][Full Text] [Related]
39. Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.
Li HY; Wang Y; Heap CR; King CH; Mundla SR; Voss M; Clawson DK; Yan L; Campbell RM; Anderson BD; Wagner JR; Britt K; Lu KX; McMillen WT; Yingling JM
J Med Chem; 2006 Mar; 49(6):2138-42. PubMed ID: 16539403
[TBL] [Abstract][Full Text] [Related]
40. Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening.
Liu X; Xie H; Luo C; Tong L; Wang Y; Peng T; Ding J; Jiang H; Li H
J Med Chem; 2010 Mar; 53(6):2661-5. PubMed ID: 20178321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
